Figure 2.
Subgroup analysis of the ASCEMBL study: risk difference with 95% CIs for MR3 achievement by 24 weeks of either asciminib or bosutinib. CRF, case report form. Reproduced with permission from Rea et al.15
Subgroup analysis of the ASCEMBL study: risk difference with 95% CIs for MR3 achievement by 24 weeks of either asciminib or bosutinib. CRF, case report form. Reproduced with permission from Rea et al.15